Clinical pipeline opportunity Target radiopharmaceuticals and theranostics for rare cancers present a clear entry point for strategic partnerships, clinical trial collaborations, and licensing discussions with research institutions and biotech firms focused on neuroendocrine tumors, glioblastoma, NSCLC, and tumor response diagnostics.

Strategic collaborations Leverage past and ongoing partnerships (NIH licensing, Brookline Capital Markets, academic centers) to accelerate co-development, manufacturing agreements, and capitalization strategies with specialized radiopharma manufacturers and contract research organizations.

Clinical leadership Recent executive hires and leadership appointments signal growing clinical development capacity; these changes create openings for advisory roles, sponsored studies, and education programs to attract clinical trial sites and investigators.

Manufacturing and supply Participation in TRP supply chain discussions and radiopharmaceutical manufacturing expertise suggests opportunities to offer, co-fund, or optimize GMP-grade production, logistics, and scale-up services for radiolabeled compounds.

Funding and visibility Publicized SNMMI presentation data and active conference participation indicate a window to engage investors and strategic partners, proposing investment theses or joint ventures around two-cycle EBTATE data and enhanced tumor targeting in GEP-NET patients.